Boehringer-Ingelheim

An extended labeling claim has added detection of three additional EGFR mutations to help ID NSCLC patients for whom Boehringer Ingelheim's Gilotrif is indicated.

The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.

In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.  

The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.

The lead investigators said that Foundation Medicine's NGS test will enable the beginning of targeted treatment within seven days of diagnosis. 

Poor patient health, tumor histology, insufficient tissue samples, and long turnaround times are some reasons doctors gave for not using EGFR status to determine care.

New survival data suggest that patients with del19 mutations should receive Gilotrif as their top option and that researchers should no longer clump different EGFR-mutated subpopulations together in research, lead study investigator Lecia Sequist said.

NEW YORK (GenomeWeb) – IDBS said this week the Boehringer Ingelheim is using IDBS' E-WorkBook Suite to help streamline and improve its research and development efforts.

NEW YORK (GenomeWeb) – The National Comprehensive Cancer Network's Oncology Research Program has awarded grants to four researchers who will investigate the efficacy of the drug nintedanib in non-small cell lung, colorectal, and gastrointestinal cancers.

Pages

The data generated by 100,000 Genomes Project is being housed on military servers due to attacks by hackers, Naked Security reports.

A new poll finds most US adults are not familiar with personalized medicine, according to HealthDay.

Vox reports that the United Nations' Convention on Biological Diversity decided against a gene drive moratorium.

In Science this week: sequencing of neuroblastomas uncovers alterations linked to prognosis, and more.